In Vitro Study of Antiadipogenic Profile of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in Human Orbital Preadiopocytes

Overview

Journal J Ocul Pharmacol Ther

Specialties Ophthalmology
Pharmacology

Date 2011 Nov 24

PMID 22107041

Citations 20

Authors

Hee Young Choi

Ji Woong Lee

Hyun Jun Park

Ji Eun Lee

Jae Ho Jung

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effect of prostaglandin F2α (PGF2α), latanoprost, travoprost, bimatoprost, and tafluprost on human orbital preadipocyte differentiation and intracellular lipid storage, and to reveal the potential mechanisms by which topical prostaglandin analogs induce orbital fat volume reduction and cause deep superior sulcus syndrome.

Methods: Human orbital adipose precursors were treated in vitro for 24 h (day 1) with PGF2α, latanoprost, travoprost, bimatoprost, and tafluprost in their commercial formulations (1:100 dilution). Expressions of adipogenic transcription factor, peroxisome proliferator-activated receptor-gamma (PPARγ), and CCAAT-enhancer-binding protein α (C/EBPα) were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) at day 7. At 14 days, cells were stained with oil red O, intracellular lipid accumulation was evaluated by lipid absorbance, and adipocyte expression marker [Lipoprotein lipase (LPL)] was determined by real-time RT-PCR.

Results: Our results showed that PGF2α and topical prostaglandin analogs down-regulated the expression of PPARγ and C/EBPα, and inhibited accumulation of intra-cytoplasmic lipid droplets and expression of LPL compared with the untreated control. Comparison between the 4 drugs showed that latanoprost had the weakest antiadipogenic effect, and bimatoprost induced the most significant reduction of adipogenesis.

Conclusion: Latanoprost, travoprost, bimatoprost, and tafluprost inhibited human preadipocyte differentiation and intracellular lipid accumulation. Morphologic and metabolic changes in orbital adipocytes caused by PGF2α analogs are a possible pathophysiologic explanation of superior eyelid deepening in patients with glaucoma.

Citing Articles

Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography.

Durmus Ece B, Yozgat Z, Bayramli H, Ece B, Aydin S J Clin Med. 2024; 13(19).

PMID: 39407871 PMC: 11478186. DOI: 10.3390/jcm13195808.

From Eye Care to Hair Growth: Bimatoprost.

Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794131 PMC: 11124470. DOI: 10.3390/ph17050561.

Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy.

Ruiz-Lozano R, Azar N, Mousa H, Quiroga-Garza M, Komai S, Wheelock-Gutierrez L Front Toxicol. 2023; 5:1067942.

PMID: 37547228 PMC: 10403269. DOI: 10.3389/ftox.2023.1067942.

Identification and characterization of adipose surface epitopes.

Onogi Y, Khalil A, Ussar S Biochem J. 2020; 477(13):2509-2541.

PMID: 32648930 PMC: 7360119. DOI: 10.1042/BCJ20190462.

Prostaglandin F2α Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts.

Itoh K, Hikage F, Ida Y, Ohguro H Invest Ophthalmol Vis Sci. 2020; 61(6):13.

PMID: 32503053 PMC: 7415291. DOI: 10.1167/iovs.61.6.13.

References

Sharif N, Crider J, Husain S, Kaddour-Djebbar I, Ansari H, Abdel-Latif A . Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003; 19(5):437-55. DOI: 10.1089/108076803322473006. View

Serrero G, Lepak N . Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997; 233(1):200-2. DOI: 10.1006/bbrc.1997.6433. View

Jayaprakasam A, Ghazi-Nouri S . Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29(6):357-9. DOI: 10.3109/01676830.2010.527028. View

Sagara T, Gaton D, Lindsey J, Gabelt B, Kaufman P, Weinreb R . Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999; 117(6):794-801. DOI: 10.1001/archopht.117.6.794. View

Tsuboi K, Sugimoto Y, Ichikawa A . Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 2002; 68-69:535-56. DOI: 10.1016/s0090-6980(02)00054-0. View

Hata A, Breyer R . Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004; 103(2):147-66. DOI: 10.1016/j.pharmthera.2004.06.003. View

Yam J, Yuen N, Chan C . Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009; 25(5):471-2. DOI: 10.1089/jop.2009.0019. View

Fujimori K, Ueno T, Nagata N, Kashiwagi K, Aritake K, Amano F . Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase. J Biol Chem. 2010; 285(12):8880-6. PMC: 2838309. DOI: 10.1074/jbc.M109.077164. View

Hardy T, Joshi N, Kelly M . Orbital volume augmentation with autologous micro-fat grafts. Ophthalmic Plast Reconstr Surg. 2007; 23(6):445-9. DOI: 10.1097/IOP.0b013e31815928f8. View

10.

Tappeiner C, Perren B, Iliev M, Frueh B, Goldblum D . [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?]. Klin Monbl Augenheilkd. 2008; 225(5):443-5. DOI: 10.1055/s-2008-1027362. View

11.

Vogel R, Strahlman E, Rittenhouse K . Adverse events associated with commonly used glaucoma drugs. Int Ophthalmol Clin. 1999; 39(2):107-24. DOI: 10.1097/00004397-199903920-00009. View

12.

Schnober D, Hofmann G, Maier H, Scherzer M, Ogundele A, Jasek M . Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010; 4:1459-63. PMC: 3009992. DOI: 10.2147/OPTH.S13720. View

13.

Sharif N, Kelly C, Crider J, Williams G, Xu S . Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2004; 19(6):501-15. DOI: 10.1089/108076803322660422. View

14.

Reginato M, Krakow S, Bailey S, Lazar M . Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998; 273(4):1855-8. DOI: 10.1074/jbc.273.4.1855. View

15.

Guenoun J, Baudouin C, Rat P, Pauly A, Warnet J, Brignole-Baudouin F . In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46(12):4594-9. DOI: 10.1167/iovs.05-0776. View

16.

Camras C . Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996; 103(1):138-47. DOI: 10.1016/s0161-6420(96)30749-5. View

17.

Serrero G, Lepak N . Endocrine and paracrine negative regulators of adipose differentiation. Int J Obes Relat Metab Disord. 1996; 20 Suppl 3:S58-64. View

18.

Ajjan R, Weetman A . New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest. 2004; 27(3):237-45. DOI: 10.1007/BF03345272. View

19.

Casson R, Selva D . Lash ptosis caused by latanoprost. Am J Ophthalmol. 2005; 139(5):932-3. DOI: 10.1016/j.ajo.2004.10.062. View

20.

Filippopoulos T, Paula J, Torun N, Hatton M, Pasquale L, Grosskreutz C . Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008; 24(4):302-7. DOI: 10.1097/IOP.0b013e31817d81df. View